2024-11-19 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Intuitive Surgical Inc. (ISRG) is a company that manufactures and sells da Vinci surgical systems, a robotic surgery system.  The cumulative return of ISRG (328.32%) significantly outperforms the S&P 500 (VOO) cumulative return (124.78%). The difference in cumulative returns is 203.54%, placing it at the 98.63rd percentile of its historical range relative to the S&P 500. This indicates a substantial outperformance compared to the benchmark index.  The provided alpha values consistently exceed 1, further supporting the significant outperformance.

**Alpha and Beta Analysis:**

The table shows a consistently high alpha, indicating significant outperformance relative to the market benchmark (S&P 500), particularly in the years 2016-2019. Beta values generally hover around 1.2-1.4, indicating higher volatility than the overall market.  While the most recent years show a slightly lower CAGR and higher MDD (Maximum Drawdown), the overall trend shows impressive performance.


**2. Recent Price Movement:**

* **Closing Price:** 531.64
* **5-Day Moving Average:** 534.16
* **20-Day Moving Average:** 520.48
* **60-Day Moving Average:** 497.22

The price is currently below the 5-day and 20-day moving averages, suggesting a short-term bearish trend. However, it remains significantly above the 60-day moving average, indicating a longer-term bullish trend.  The last market price of 531.79 is close to the closing price and doesn't indicate a significant sudden jump or drop.


**3. Technical Indicators and Relative Divergence:**

* **RSI (Relative Strength Index):** 62.2 -  Suggests the stock is neither overbought nor oversold, indicating a neutral sentiment.
* **PPO (Percentage Price Oscillator):** 0.07 - A positive value suggests bullish momentum, although relatively weak.
* **20-Day Relative Divergence Change:** -0.65 - Indicates a recent short-term weakening in relative performance compared to the S&P 500.
* **Expected Return (2+ years):** 2.29% -  This suggests a modest outperformance compared to the S&P 500 over the long term, assuming continued positive trends.


**4. Recent Financials and Outlook:**

The provided financial data shows consistent revenue growth and high profit margins. EPS remains relatively stable, though there is some minor fluctuation. The most recent earnings reports (October 18th, 2024) show positive EPS and Revenue figures exceeding some previous quarters.  Further analysis of these figures against analyst predictions (which are not provided here) is crucial to properly assess the performance.

**5. Quarterly Financial Data Analysis:**

**(1) Revenue and Profitability:** Revenue consistently remains above $1.7B across all quarters, with a strong profit margin consistently exceeding 65%. This signifies high profitability and strong financial health.

**(2) Capital and Profitability:** Equity shows a steady increase, and while ROE fluctuates, it remains above 3% in most quarters.


**6. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and Finbold.  I cannot access real-time information, so I cannot provide a summary of recent news and analyst opinions.  Please refer to these sources for the most up-to-date information.)*  Search for "ISRG earnings" and "ISRG stock analysis" on these platforms to gather the latest insights.  Pay close attention to any recent FDA approvals, regulatory updates, competitive landscape changes, or changes in market outlook for robotic surgery.

**7. Comprehensive Analysis:**

ISRG has shown exceptional long-term performance compared to the S&P 500. However, recent short-term indicators suggest a potential slowdown in relative momentum.  The stock's valuation should be analyzed based on the combination of fundamental data (strong financials, high margins, and consistent revenue) and technical indicators (slightly bearish short-term trends but still strong longer-term trends).  The recent earnings report needs to be assessed against analyst expectations to provide a complete picture. News and analyst opinions will further refine the outlook, especially concerning market sentiment and any potential headwinds.  The high expected return over the long term suggests it could remain a viable investment for long-term investors with a higher risk tolerance.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be based on thorough due diligence and consideration of your personal risk tolerance and financial goals.  Consult with a qualified financial advisor before making any investment decisions.
